Medical progress Brucellosis

New England Journal of Medicine

Volumn 352, Issue 22, 2005, Pages

  Pappas, Georgios ^a   Akritidis, Nikolaos ^a   Bosilkovski, Mile ^a   Tsianos, Epameinondas ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BRUCELLA VACCINE; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; GENTAMICIN; LEVOFLOXACIN; MOXIFLOXACIN; NETILMICIN; OFLOXACIN; QUINOLONE DERIVATIVE; RIFAMPICIN; STEROID; STREPTOMYCIN; BACTERIUM ANTIBODY;

BLOOD CULTURE; BONE MARROW CULTURE; BRUCELLA; BRUCELLA MELITENSIS; BRUCELLOSIS; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC TEST; DISEASE TRANSMISSION; DRUG DOSE REGIMEN; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOME; GRANULOMATOSIS; HUMAN; IMMUNE RESPONSE; META ANALYSIS; MORBIDITY; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEROLOGY; BACTERIAL GENOME; CLASSIFICATION; DAIRY PRODUCT; DRUG COMBINATION; GENETICS; IMMUNOLOGY; MICROBIOLOGY; PATHOGENICITY; RECURRENT DISEASE;

ANTIBODIES, BACTERIAL; BRUCELLA; BRUCELLA MELITENSIS; BRUCELLOSIS; DAIRY PRODUCTS; DOXYCYCLINE; DRUG THERAPY, COMBINATION; GENOME, BACTERIAL; HUMANS; PREVALENCE; RECURRENCE; RIFAMPIN; STREPTOMYCIN;

EID: 19644363222     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra050570     Document Type: Review

References (99)

1. Capasso L. Bacteria in two-millennia-old cheese, and related epizoonoses in Roman populations. J Infect 2002;45:122-7.
2. Corbel MJ. Brucellosis: an overview. Emerg Infect Dis 1997;3:213-21.
3. Young EJ. An overview of human brucellosis. Clin Infect Dis 1995;21:283-9.
4. Fosgate GT, Carpenter TE, Chomel BB, Case JT, DeBess EE, Reilly KF. Time-space clustering of human brucellosis, California, 1973-1992. Emerg Infect Dis 2002;8:672-8. [Erratum, Emerg Infect Dis 2002;8:877.]
5. Chang MH, Glynn MK, Groseclose SL. Endemic, notifiable bioterrorism-related diseases, United States, 1992-1999. Emerg Infect Dis 2003;9:556-64.
6. Moreno E, Stackebrandt E, Dorsch M, Wolters J, Busch M, Mayer H. Brucella abortus 16S rRNA and lipid A reveal a phylogenetic relationship with members of the alpha-2 subdivision of the class Proteobacteria. J Bacteriol 1990;172:3569-76.
7. Ewalt DR, Payeur JE, Martin BM, Cummins DR, Miller WG. Characteristics of a Brucella species from a bottlenose dolphin (Tursiops truncatus). J Vet Diagn Invest 1994;6:448-52.
8. Ross HM, Jahans KL, MacMillan AP, Reid RJ, Thompson PM, Foster G. Brucella species infection in North Sea seal and cetacean populations. Vet Rec 1996;138:647-8.
9. Al Dahouk S, Tomaso H, Nockler K, Neubauer H, Frangoulidis D. Laboratory-based diagnosis of brucellosis - a review of the literature. Part I: techniques for direct detection and identification of Brucella spp. Clin Lab 2003;49:487-505.
10. Cloeckaert A, Vizcaino N, Paquet JY, Bowden RA, Elzer PH, Major outer membrane proteins of Brucella spp.: past, present and future. Vet Microbiol 2002;90: 229-47.
11. Moreno E, Cloeckaert A, Moriyon I. Brucella evolution and taxonomy. Vet Microbiol 2002;90:209-27.
12. DelVecchio VG, Kapatral V, Redkar RJ, et al. The genome sequence of the facultative intracellular pathogen Brucella melitensis. Proc Natl Acad Sci U S A 2002;99:443-8.
13. Sanchez DO, Zandomeni RO, Cravero S, et al. Gene discovery through genomic sequencing of Brucella abortus. Infect Immun 2001;69:865-8.
14. Paulsen IT, Seshadri R, Nelson KE, et al. The Brucella suis genome reveals fundamental similarities between animal and plant pathogens and symbionts. Proc Natl Acad Sci U S A 2002;99:13148-53.
15. Dornand J, Gross A, Lafont V, Liautard J, Oliaro J, Liautard JP. The innate immune response against Brucella in humans. Vet Microbiol 2002;90:383-94.
16. Detilleux PC, Deyoe BL, Cheville NF. Effect of endocytic and metabolic inhibitors on the internalization and intracellular growth of Brucella abortus in Vero cells. Am J Vet Res 1991;52:1658-64.
17. Gross A, Terraza A, Ouahrani-Bettache S, Liautard JP, Dornand J. In vitro Brucella suis infection prevents the programmed cell death of human monocytic cells. Infect Immun 2000;68:342-51.
18. Guzman-Verri C, Manterola L, Sola-Landa A, et al. The two-component system BvrR/BvrS essential for Brucella abortus virulence regulates the expression of outer membrane proteins with counterparts in members of the Rhizobiaceae. Proc Nad Acad Sci U S A 2002;99:12375-80.
19. Arenas GN, Staskevich AS, Aballay A, Mayorga LS. Intracellular trafficking of Brucella abortus in J774 macrophages. Infect Immun 2000;68:4255-63.
20. Pizarro-Cerda J, Moreno E. Sanguedolce V, Mege JL, Gorvel JP. Virulent Brucella abortus prevents lysosome fusion and is distributed within autophagosome-like compartments. Infect Immun 1998;66:2387-92.
21. Celli J, de Chastellier C, Franchini DM, Pizarro-Cerda J, Moreno E, Gorvel JP. Brucella evades macrophage killing via VirB-dependent sustained interactions with the endoplasmic reticulum. J Exp Med 2003; 198:545-56.
22. Gorvel JP, Moreno E. Brucella intracellular life: from invasion to intracellular replication. Vet Microbiol 2002;90:281-97.
23. Salmeron I, Rodriguez-Zapata M, Salmeron O, Manzano L, Vaquer S, Alvarez-Mon M. Impaired activity of natural killer cells in patients with acute brucellosis. Clin Infect Dis 1992;15:764-70.
24. Rodriguez-Zapata M, Reyes E, Sanchez L, Espinosa A, Solera J, Alvarez-Mon M. Defective reactive oxygen metabolite generation by macrophages from acute brucellosis patients. Infection 1997;25:187-8.
25. Ko J, Gendron-Fitzpatrick A, Splitter GA. Susceptibility of IFN regulatory factor-1 and IFN consensus sequence binding protein-deficient mice to brucellosis. J Immunol 2002;168:2433-40.
26. Bertotto A, Gerli R, Spinozzi F, et al. Lymphocytes bearing the gamma delta T cell receptor in acute Brucella melitensis infection. Eur J Immunol 1993;23:1177-80.
27. Ottones F, Dornand J, Naroeni A, Liautard JP, Favero J. V gamma 9V delta 2 T cells impair intracellular multiplication of Brucella suis in autologous monocytes through soluble factor release and contact-dependent cytotoxic effect. J Immunol 2000;165:7133-9.
28. Yingst S, Hoover DL. T cell immunity to brucellosis. Crit Rev Microbiol 2003;29: 313-31.
29. Zhan Y, Cheers C. Endogenous gamma interferon mediates resistance to Brucella abortus infection. Infect Immun 1993;61: 4899-901.
30. Bravo MJ, de Dios Colmenero J, Alonso A, Caballero A. Polymorphisms of the interferon gamma and interleukin 10 genes in human brucellosis. Eur J Immunogenet 2003;30:433-5.
31. Demirdag K, Ozden M, Kalkan A, Godekmerdan A, Sirri Kilic S. Serum cytokine levels in patients with acute brucellosis and their relation to the traditional inflammatory markers. FEMS Immunol Med Microbiol 2003;39:149-53.
32. Ahmed K, Al-Matrouk KA, Martinez G, Oishi K, Rotimi VO, Nagatake T. Increased serum levels of interferon-gamma and interleukin-12 during human brucellosis. Am J Trop Med Hyg 1999;61:425-7.
33. Jubier-Maurin V, Boigegrain RA, Cloeckaert A, et al. Major outer membrane protein Omp25 of Brucella suis is involved in inhibition of tumor necrosis factor alpha production during infection of human macrophages. Infect Immun 2001;69:4823-30.
34. Zhan Y, Cheers C. Endogenous interleukin-12 is involved in resistance to Brucella abortus infection. Infect Immun 1995;63: 1387-90.
35. Almuneef MA, Memish ZA, Balkhy HH, et al. Importance of screening household members of acute brucellosis cases in endemic areas. Epidemiol Infect 2004;132: 533-40.
36. Smart JK. History of chemical and bio logical warfare. In: Sidell FR, Takafuji ET, Franz DR, eds. Textbook of military medicine. Part I. Warfare, weaponry, and the casualty. Vol. 3. Medical aspects of chemical and biological warfare. Washington, D.C.: Government Printing Office, 1997:9-86.
37. Kaufmann AF, Meltzer MI, Schmid GP. The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable? Emerg Infect Dis 1997;3:83-94.
38. Ergonul O, Celikbas A, Tezeren D, Guvener E, Dokuzoguz B. Analysis of risk factors for laboratory-acquired brucella infections. J Hosp Infect 2004;56:223-7.
39. Sohn AH, Probert WS, Glaser CA, et al. Human neurobrucellosis with intracerebral granuloma caused by a marine mammal Brucella spp. Emerg Infect Dis 2003;9:485-8.
40. Dokuzoguz B, Ergonul O, Baykam N, et al. Characteristics of B. melitensis versus B. abortus bacteraemias. J Infect 2005;50: 41-5.
41. Bodur H, Balaban N, Aksaray S, et al. Biotypes and antimicrobial susceptibilities of Brucella isolates. Scand J Infect Dis 2003; 35:337-8.
42. Colmenero JD, Reguera JM, Martos F, et al. Complications associated with Brucella melitensis infection: a study of 530 cases. Medicine (Baltimore) 1996;75:195-211. [Erratum, Medicine (Baltimore) 1997;76: 139.]
43. Bosilkovski M, Krteva L, Caparoska S, Dimzova M. Hip arthritis in brucellosis: a study of 33 cases in the Republic of Macedonia (FYROM). Int J Clin Pract 2004;58: 1023-7.
44. Ariza J, Pujol M, Valverde J, et al. Brucellar sacroiliitis: findings in 63 episodes and current relevance. Clin Infect Dis 1993;16: 761-5.
45. Solera J, Lozano E, Martinez-Alfaro E, Espinosa A, Castillejos ML, Abad L. Brucellar spondylitis: review of 35 cases and literature survey. Clin Infect Dis 1999;29:1440-9.
46. Bravo MJ, Colmenero JD, Alonso A, Caballero A. HLA-B*39 allele confers susceptibility to osteoarticular complications in human brucellosis. J Rheumatol 2003;30: 1051-3.
47. Navarro-Martinez A, Solera J, Corredoira J, et al. Epididymoorchitis due to Brucella mellitensis: a retrospective study of 59 patients. Clin Infect Dis 2001;33:2017-22.
48. Khan MY, Mah MW, Memish ZA. Brucellosis in pregnant women. Clin Infect Dis 2001;32:1172-7.
49. Ariza J, Pigrau C, Canas C, et al. Current understanding and management of chronic hepatosplenic suppurative brucellosis. Clin Infect Dis 2001;32:1024-33.
50. Cervantes F, Bruguera M, Carbonell J, Force L, Webb S. Liver disease in brucellosis: a clinical and pathological study of 40 cases. Postgrad Med J 1982;58:346-50.
51. Akritidis N, Pappas G. Ascites caused by brucellosis: a report of two cases. Scand J Gastroenterol 2001;36:110-2.
52. Shakir RA, Al-Din AS, Araj GF, Lulu AR, Mousa AR, Saadah MA. Clinical categories of neurobrucellosis: a report on 19 cases. Brain 1987;110:213-23.
53. Reguera JM, Alarcon A, Miralles F, Pachon J, Juarez C, Colmenero JD. Brucella endocarditis: clinical, diagnostic, and therapeutic approach. Eur J Clin Microbiol Infect Dis 2003;22:647-50.
54. Pappas G, Bosilkovski M, Akritidis N, Mastora M, Krteva L, Tsianos E. Brucellosis and the respiratory system. Clin Infect Dis 2003;37:e95-e99.
55. Young EJ, Tarry A, Genta RM, Ayden N, Gotuzzo E. Thrombocytopenic purpura associated with brucellosis: report of 2 cases and literature review. Clin Infect Dis 2000; 31:904-9.
56. Pappas G, Kitsanou M, Christou L, Tsianos E. Immune thrombocytopenia attributed to brucellosis and other mechanisms of Brucella-induced thrombocytopenia. Am J Hematol 2004;75:139-41.
57. Solera J, Martinez-Alfaro E, Espinosa A, Castillejos ML, Geijo P, Rodriguez-Zapata M. Multivariate model for predicting relapse in human brucellosis. J Infect 1998;36:85-92.
58. Ariza J, Corredoira J, Pallares R, et al. Characteristics of and risk factors for relapse of brucellosis in humans. Clin Infect Dis 1995;20:1241-9.
59. Shaalan MA, Memish ZA, Mahmoud SA, et al. Brucellosis in children: clinical observations in 115 cases. Int J Infect Dis 2002;6:182-6.
60. Moreno S, Ariza J, Espinosa FJ, et al. Brucellosis in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 1998;17:319-26.
61. Memish Z, Mah MW, Al Mahmoud S, Al Shaalan M, Khan MY. Brucella bacteraemia: clinical and laboratory observations in 160 patients. J Infect 2000;40:59-63.
62. Bannatyne RM, Jackson MC, Memish Z. Rapid diagnosis of Brucella bacteremia by using the BACTEC 9240 system. J Clin Microbiol 1997;35:2673-4.
63. Yagupsky P. Detection of Brucellae in blood cultures. J Clin Microbiol 1999;37: 3437-42.
64. Gotuzzo E, Carrillo C, Guerra J, Llosa L. An evaluation of diagnostic methods for brucellosis - the value of bone marrow culture. J Infect Dis 1986;153:122-5.
65. Young EJ. Serologic diagnosis of human brucellosis: analysis of 214 cases by agglutination tests and review of the literature. Rev Infect Dis 1991;13:359-72.
66. Araj GF. Human brucellosis: a classical infectious disease with persistent diagnostic challenges. Clin Lab Sci 1999;12:207-12.
67. Casao MA, Smits HL, Navarro E, Solera J. Clinical utility of a dipstick assay in patients with brucellosis: correlation with the period of evolution of the disease. Clin Microbiol Infect 2003;9:301-5.
68. Al Dahouk S, Tomaso H, Nockler K, Neubauer H, Frangoulidis D. Laboratory-based diagnosis of brucellosis - a review of the literature. Part II: serological tests for brucellosis. Clin Lab 2003;49:577-89.
69. Almuneef M, Memish ZA. Prevalence of Brucella antibodies after acute brucellosis. J Chemother 2003;15:148-51.
70. Araj GF, Lulu AR, Khateeb MI, Saadah MA, Shakir RA. ELISA versus routine tests in the diagnosis of patients with systemic and neurobrucellosis. APMIS 1988;96:171-6.
71. Ariza J, Pellicer T, Pallares R, Foz A, Gudiol F. Specific antibody profile in human brucellosis. Clin Infect Dis 1992;14:131-40.
72. Fekete A, Bantle JA, Hailing SM, Sanborn MR. Preliminary development of a diagnostic test for Brucella using polymerase chain reaction. J Appl Bacteriol 1990;69: 216-27.
73. Romero C, Gamazo C, Pardo M, Lopez-Goni I. Specific detection of Brucella DNA by PCR. J Clin Microbiol 1995;33:615-7.
74. Nimri LF. Diagnosis of recent and relapsed cases of human brucellosis by PCR assay. BMC Infect Dis 2003;3:5.
75. Baily GG, Krahn JB, Drasar BS, Stoker NG. Detection of Brucella melitensis and Brucella abortus by DNA amplification. J Trop Med Hyg 1992;95:271-5.
76. Morata P, Queipo-Ortuno MI, Reguera JM, Garcia-Ordonez MA, Pichardo C, Colmenero JD. Posttreatment follow-up of brucellosis by PCR assay. J Clin Microbiol 1999;37:4163-6.
77. Navarro E, Escribano J, Fernandez J, Solera J. Comparison of three different PCR methods for detection of Brucella spp in human blood samples. FEMS Immunol Med Microbiol 2002;34:147-51.
78. Matar GM, Khneisser IA, Abdelnoor AM. Rapid laboratory confirmation of human brucellosis by PCR analysis of a target sequence on the 31-kilodalton Brucella antigen DNA. J Clin Microbiol 1996;34:477-8.
79. Redkar R, Rose S, Bricker B, DelVecchio V. Real-time detection of Brucella abortus, Brucella melitensis and Brucella suis. Mol Cell Probes 2001;15:43-52.
80. Probert WS, Schrader KN, Khuong NY, Bystrom SL, Graves MH. Real-time multiplex PCR assay for detection of Brucella spp., B. abortus, and B. melitensis. J Clin Microbiol 2004;42:1290-3.
81. Queipo-Ortuno MI, Colmenero JD, Baeza G, Morata P. Comparison between LightCycler Real-Time Polymerase Chain Reaction (PCR) assay with serum and PCR-enzyme-linked immunosorbent assay with whole blood samples for the diagnosis of human brucellosis. Clin Infect Dis 2005;40: 260-4.
82. Vrioni G, Gartzonika C, Kostoula A, Boboyianni C, Papadopoulou C, Levidiotou S. Application of a polymerase chain reaction enzyme immunoassay in peripheral whole blood and serum specimens for diagnosis of acute human brucellosis. Eur J Clin Microbiol Infect Dis 2004;23:194-9.
83. Morata P, Queipo-Ortuno MI, Reguera JM, Garcia-Ordonez MA, Cardenas A, Colmenero JD. Development and evaluation of a PCR-enzyme-linked immunosorbent assay for diagnosis of human brucellosis. J Clin Microbiol 2003;41:144-8.
84. McDonald R, Cao T, Borschel R. Multiplexing for the detection of multiple biowarfare agents shows promise in the field. Mil Med 2001;166:237-9.
85. Navarro E, Casao MA, Solera J. Diagnosis of human brucellosis using PCR. Expert Rev Mol Diagn 2004;4:115-23.
86. Solera J, Geijo P, Largo J, et al. A randomized, double-blind study to assess the optimal duration of doxycycline treatment for human brucellosis. Clin Infect Dis 2004; 39:1776-82.
87. Pappas G, Akritidis N, Tsianos E. Effective treatments in the management of brucellosis. Expert Opin Pharmacother 2005;2: 201-9.
88. Solera J, Martinez-Alfaro E, Saez L. Meta-analysis of the efficacy of rifampicin and doxycycline in the treatment of human brucellosis. Med Clin (Barc) 1994;102:731-8. (In Spanish.)
89. Colmenero JD, Fernandez-Gallardo LC, Agundez JA, Sedeno J, Benitez J, Valverde E. Possible implications of doxycycline-rifampin interaction for treatment of brucellosis. Antimicrob Agents Chemother 1994;38: 2798-802.
90. Solera J, Martinez-Alfaro E, Espinosa A. Recognition and optimum treatment of brucellosis. Drugs 1997;53:245-56.
91. Karabay O, Sencan I, Kayas D, Sahin I. Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial [ISRCTN11871179]. BMC Infect Dis 2004; 4:18.
92. Lopez-Merino A, Contreras-Rodriguez A, Migranas-Ortiz R, et al. Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand J Infect Dis 2004;36:636-8.
93. Solera J, Beato JL, Martinez-Alfaro E, Segura JC, de Tomas E. Azirhromycin and gentamicin therapy for the treatment of humans with brucellosis. Clin Infect Dis 2001;32:506-9.
94. McLean DR, Russell N, Khan MY. Neu robrucellosis: clinical and therapeutic features. Clin Infect Dis 1992;15:582-90.
95. Pappas G, Seitaridis S, Akritidis N, Tsianos E. Treatment of brucella spondylitis: lessons from an impossible meta-analysis and initial report of efficacy of a fluoroquinolone-containing regimen. Int J Antimicrob Agents 2004;24:502-7.
96. Lubani MM, Dudin KI, Sharda DC, et al. A multicenter therapeutic study of 1100 children with brucellosis. Pediatr Infect Dis J 1989;8:75-8.
97. Schurig GG, Sriranganathan N, Corbel MJ. Brucellosis vaccines: past, present and future. Vet Microbiol 2002;90:479-96.
98. Hadjichristodoulou C, Voulgaris P, Toulieres L, et al. Tolerance of the human brucellosis vaccine and the intradermal reaction test for brucellosis. Eur J Clin Microbiol Infect Dis 1994;13:129-34.
99. Ko J, Splitter GA. Molecular host-pathogen interaction in brucellosis: current understanding and ruture approaches to vaccine development for mice and humans. Clin Microbiol Rev 2003;16:65-78.